Barclays’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.23M | Sell |
249,807
-109,341
| -30% | -$2.46M | ﹤0.01% | 1791 |
|
|
2025
Q4 | $8.26M | Sell |
359,148
-66,203
| -16% | -$2.18M | ﹤0.01% | 1827 |
|
|
2025
Q3 | $12.8M | Buy |
425,351
+246,740
| +138% | +$7.4M | ﹤0.01% | 1498 |
|
|
2025
Q2 | $6.49M | Buy |
178,611
+35,730
| +25% | +$1.29M | ﹤0.01% | 1895 |
|
|
2025
Q1 | $5.17M | Sell |
142,881
-63,227
| -31% | -$2.63M | ﹤0.01% | 1883 |
|
|
2024
Q4 | $8.67M | Buy |
206,108
+126,562
| +159% | +$6.28M | ﹤0.01% | 1680 |
|
|
2024
Q3 | $4.42M | Buy |
79,546
+16,633
| +26% | +$847K | ﹤0.01% | 2195 |
|
|
2024
Q2 | $2.59M | Sell |
62,913
-55,860
| -47% | -$2.39M | ﹤0.01% | 1956 |
|
|
2024
Q1 | $5.55M | Sell |
118,773
-47,969
| -29% | -$2.26M | ﹤0.01% | 1780 |
|
|
2023
Q4 | $7.97M | Buy |
166,742
+46,049
| +38% | +$1.79M | ﹤0.01% | 1703 |
|
|
2023
Q3 | $4.3M | Buy |
120,693
+18,552
| +18% | +$735K | ﹤0.01% | 1409 |
|
|
2023
Q2 | $4.71M | Buy |
102,141
+10,474
| +11% | +$486K | ﹤0.01% | 1381 |
|
|
2023
Q1 | $3.68M | Sell |
91,667
-32,920
| -26% | -$1.41M | ﹤0.01% | 1754 |
|
|
2022
Q4 | $5.77M | Buy |
124,587
+8,997
| +8% | +$354K | ﹤0.01% | 1520 |
|
|
2022
Q3 | $4.79M | Buy |
115,590
+95,515
| +476% | +$4.91M | 0.01% | 1194 |
|
|
2022
Q2 | $1.2M | Buy |
20,075
+473
| +2% | +$29.1K | ﹤0.01% | 2211 |
|
|
2022
Q1 | $1.42M | Sell |
19,602
-3,828
| -16% | -$266K | ﹤0.01% | 2143 |
|
|
2021
Q4 | $1.97M | Buy |
23,430
+18,715
| +397% | +$1.52M | ﹤0.01% | 2387 |
|
|
2021
Q3 | $425K | Sell |
4,715
-19,665
| -81% | -$1.78M | ﹤0.01% | 3267 |
|
|
2021
Q2 | $2.33M | Sell |
24,380
-47,296
| -66% | -$4.93M | ﹤0.01% | 2090 |
|
|
2021
Q1 | $8.16M | Buy |
71,676
+48,152
| +205% | +$6.56M | ﹤0.01% | 1177 |
|
|
2020
Q4 | $3.26M | Sell |
23,524
-74,107
| -76% | -$8.79M | ﹤0.01% | 1840 |
|
|
2020
Q3 | $8.03M | Buy |
97,631
+63,161
| +183% | +$5.24M | ﹤0.01% | 1129 |
|
|
2020
Q2 | $2.7M | Sell |
34,470
-117,302
| -77% | -$7.76M | ﹤0.01% | 1843 |
|
|
2020
Q1 | $6.74M | Buy |
151,772
+38,561
| +34% | +$2M | 0.01% | 1246 |
|
|
2019
Q4 | $4.83M | Buy |
113,211
+86,164
| +319% | +$3.56M | ﹤0.01% | 2040 |
|
|
2019
Q3 | $1.16M | Sell |
27,047
-8,287
| -23% | -$450K | ﹤0.01% | 3519 |
|
|
2019
Q2 | $2.24M | Buy |
35,334
+11,670
| +49% | +$743K | ﹤0.01% | 2763 |
|
|
2019
Q1 | $1.64M | Buy |
23,664
+17,400
| +278% | +$994K | ﹤0.01% | 2792 |
|
|
2018
Q4 | $273K | Sell |
6,264
-20,985
| -77% | -$1.15M | ﹤0.01% | 4353 |
|
|
2018
Q3 | $2.08M | Buy |
27,249
+16,246
| +148% | +$1.32M | ﹤0.01% | 2828 |
|
|
2018
Q2 | $846K | Sell |
11,003
-602
| -5% | -$38.9K | ﹤0.01% | 3462 |
|
|
2018
Q1 | $592K | Buy |
11,605
+2,622
| +29% | +$132K | ﹤0.01% | 3798 |
|
|
2017
Q4 | $416K | Buy |
8,983
+5,594
| +165% | +$274K | ﹤0.01% | 4040 |
|
|
2017
Q3 | $180K | Buy |
3,389
+1,747
| +106% | +$104K | ﹤0.01% | 4514 |
|
|
2017
Q2 | $102K | Sell |
1,642
-21,943
| -93% | -$1.32M | ﹤0.01% | 4891 |
|
|
2017
Q1 | $1.6M | Buy |
23,585
+18,282
| +345% | +$1.39M | ﹤0.01% | 2307 |
|
|
2016
Q4 | $373K | Sell |
5,303
-29,740
| -85% | -$2.11M | ﹤0.01% | 3647 |
|
|
2016
Q3 | $2.48M | Buy |
35,043
+32,566
| +1,315% | +$2.08M | ﹤0.01% | 1812 |
|
|
2016
Q2 | $121K | Sell |
2,477
-2,562
| -51% | -$166K | ﹤0.01% | 4272 |
|
|
2016
Q1 | $318K | Buy |
5,039
+3,542
| +237% | +$232K | ﹤0.01% | 3502 |
|
|
2015
Q4 | $167K | Sell |
1,497
-10,365
| -87% | -$1.04M | ﹤0.01% | 4054 |
|
|
2015
Q3 | $1.14M | Sell |
11,862
-8,883
| -43% | -$1.02M | ﹤0.01% | 2595 |
|
|
2015
Q2 | $2.12M | Buy |
20,745
+20,010
| +2,722% | +$1.55M | ﹤0.01% | 2178 |
|
|
2015
Q1 | $45K | Buy |
735
+65
| +10% | +$3.61K | ﹤0.01% | 5360 |
|
|
2014
Q4 | $29K | Buy |
670
+426
| +175% | +$19.5K | ﹤0.01% | 6089 |
|
|
2014
Q3 | $14K | Buy |
244
+125
| +105% | +$6.29K | ﹤0.01% | 6699 |
|
|
2014
Q2 | $6K | Sell |
119
-62
| -34% | -$2.55K | ﹤0.01% | 7072 |
|
|
2014
Q1 | $9K | Buy |
+181
| New | +$9.32K | ﹤0.01% | 6973 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Barclays's RARE Position: Q1 2026 in Review
Barclays reduced its Ultragenyx Pharmaceutical (RARE) stake by 30% in Q1 2026, selling an estimated $2.46M and leaving 249,807 shares worth $5.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1791.
Barclays first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $12.8M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Barclays held 249,807 shares of Ultragenyx Pharmaceutical worth $5.23M as of Q1 2026.
- Barclays sold 109,341 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.46M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1791 holding.
- Barclays first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- Barclays's Ultragenyx Pharmaceutical position peaked at $12.8M in Q3 2025.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.